Algernon Pharmaceuticals (Algernon Pharmaceuticals) Change In Payables And Accrued Expense : $0.89 Mil (TTM As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Change In Payables And Accrued Expense?

Algernon Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2024 was $0.45 Mil. It means Algernon Pharmaceuticals's Accounts Payable & Accrued Expense increased by $0.45 Mil from Nov. 2023 to Feb. 2024 .

Algernon Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2023 was $0.05 Mil. It means Algernon Pharmaceuticals's Accounts Payable & Accrued Expense increased by $0.05 Mil from Aug. 2022 to Aug. 2023 .

Algernon Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Algernon Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Change In Payables And Accrued Expense Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.10

0.31

0.29

1.18

0.05

Algernon Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	0.05	0.25	0.14	0.45

Algernon Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89 Mil.

Algernon Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.